High-density Lipoprotein (HDL) Cholesterol in Women Taking Tibolone (TibFen)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00809068|
Recruitment Status : Completed
First Posted : December 16, 2008
Last Update Posted : February 2, 2010
Tibolone (Livial) has been shown in previous studies to lower HDL cholesterol by up to 40%.
This study aims to study the effects of fenofibrate on HDL and subfractions in women taking tibolone.
|Condition or disease||Intervention/treatment||Phase|
|HDL Cholesterol||Drug: fenofibrate and tibolone Drug: tibolone||Phase 4|
Tibolone decreases plasma concentrations of HDL cholesterol and HDL-apoA1 and pre-beta HDL, consistent with a pro-atherogenic effect. The mechanism of tibolone on HDL cholesterol has been suggested to result from an acceleration of the catabolism of HDL by stimulation of hepatic lipase with no effect on cellular cholesterol efflux.
PPAR-a agonists, in particular fenofibrate, improve HDL metabolism by increasing the expression and hepatic secretion of HDL apoAI and apoAII.
We hypothesise that fenofibrate will rectify the perturbations on HDL metabolism wrought by tibolone.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Effects of Tibolone and PPARα-agonist on HDL Metabolism in Postmenopausal Women|
|Study Start Date :||August 2005|
|Actual Primary Completion Date :||August 2009|
|Actual Study Completion Date :||October 2009|
Active Comparator: 1
fenofibrate and tibolone
Drug: fenofibrate and tibolone
fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks
Sham Comparator: 2
tibolone 2.5 mg daily 23 weeks
Other Name: Livial
- HDL subpopulation analysis [ Time Frame: August 2009 ]
- Increase in HDL subpopulations [ Time Frame: December 2009 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00809068
|Australia, Western Australia|
|Keogh Institute for Medical Research, 'A' Block 3rd Floor, QE II Medical Centre, Nedlands|
|Perth, Western Australia, Australia, 6009|
|Principal Investigator:||Bronwyn G Stuckey, MBBS FRACP||Keogh Institute for Medical Research|
|Principal Investigator:||Gerald F Watts, MD PhD FRACP||School pf Medicine and Pharmacology, Royal Perth Hospital.|
|Principal Investigator:||Rosalind Hampton, BSc MBBS||Keogh Institute for Medical Research|
|Principal Investigator:||Hugh Barrett, BAgSc PhD||School of Medicine and Pharmacology, Royal Perth Hospital|